Caspofungin - PharmaKB

Cancidas, Cancidas (previously caspofungin msd)(caspofungin)

Cancidas (caspofungin) is a small molecule pharmaceutical. Caspofungin was first approved as Cancidas on 2001-01-26. It is used to treat aspergillosis, candidemia, and mycoses in the USA. It has been approved in Europe to treat aspergillosis and candidiasis.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

Cancidas (generic drugs available since 2017-09-29)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Caspofungin acetate

Tradename	Company	Number	Date	Products
CASPOFUNGIN ACETATE	Fresenius Kabi	N-206110 RX	2016-12-30	2 products
CANCIDAS	Merck KGaA	N-021227 RX	2001-01-26	2 products, RLD, RS

Labels

FDA

EMA

Brand Name	Status	Last Update
cancidas	New Drug Application	2023-11-20
caspofungin acetate	ANDA	2023-05-02

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
aspergillosis	EFO_0007157	D001228	B44
candidemia	EFO_1001282	D058387	—
mycoses	—	D009181	B35-B49

Agency Specific

FDA

EMA

No data

Patent Expiration

Patent	Expires	Flag	FDA Information
Caspofungin Acetate, Caspofungin Acetate, Fresenius Kabi Usa
9636407	2032-12-21	DP

ATC Codes

J: Antiinfectives for systemic use

— J02: Antimycotics for systemic use

— J02A: Antimycotics for systemic use

— J02AX: Other antimycotics for systemic use in atc

— J02AX04: Caspofungin

HCPCS

Code	Description
J0637	Injection, caspofungin acetate, 5 mg

Clinical

Clinical Trials

86 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Mycoses	D009181	—	B35-B49	—	7	11	1	2	21
Invasive candidiasis	D058365	EFO_1001283	B37	—	4	6	1	1	12
Candidemia	D058387	EFO_1001282	—	—	1	6	1	3	11
Invasive pulmonary aspergillosis	D055744	—	B44.0	1	3	—	2	1	6
Critical illness	D016638	—	—	—	—	—	1	3	4
Liver transplantation	D016031	EFO_0010682	—	—	1	1	1	—	3
Invasive hydatidiform mole	D002820	—	D39.2	—	—	1	1	1	3
Pneumocystis pneumonia	D011020	EFO_0007448	B59	—	—	—	1	1	2
Septic shock	D012772	—	A48.3	—	—	—	1	1	2
Hematologic neoplasms	D019337	—	—	—	—	—	1	—	1

Show 5 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Candidiasis	D002177	—	B37	—	4	5	—	3	12
Fungemia	D016469	—	B49	—	2	3	—	—	5
Neutropenia	D009503	—	D70	—	1	2	—	1	4
Leukemia	D007938	—	C95	—	1	1	—	1	3
Neoplasms	D009369	—	C80	—	2	1	—	—	3
Myeloid leukemia acute	D015470	—	C92.0	1	1	1	—	—	2
Oral candidiasis	D002180	EFO_0007406	B37.0	—	1	1	—	—	2
Pneumocystis	D011010	—	—	—	—	1	—	—	1
Aspergillus	D001230	—	—	—	—	1	—	—	1
Intraabdominal infections	D059413	—	—	—	—	1	—	—	1

Show 5 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	—	1	—	—	4	5
Aspergillosis	D001228	EFO_0007157	B44	—	3	—	—	1	4
Hematopoietic stem cell transplantation	D018380	—	—	—	2	—	—	—	2
Hiv infections	D015658	EFO_0000764	B20	—	1	—	—	1	2
Fever	D005334	HP_0001945	R50.9	—	1	—	—	—	1

Indications Phases 1

No data

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Invasive fungal infections	D000072742	—	—	—	—	—	—	5	5
Shock	D012769	—	R57.1	—	—	—	—	1	1
Fusariosis	D060585	EFO_1001795	—	—	—	—	—	1	1
Febrile neutropenia	D064147	—	—	—	—	—	—	1	1
Sarcoma	D012509	—	—	—	—	—	—	1	1
Lymphoma	D008223	—	C85.9	—	—	—	—	1	1
Neuroblastoma	D009447	EFO_0000621	—	—	—	—	—	1	1
Kidney neoplasms	D007680	EFO_0003865	C64	—	—	—	—	1	1
Hot flashes	D019584	—	—	—	—	—	—	1	1
Pharmacokinetics	D010599	—	—	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Caspofungin
INN	caspofungin
Description	Caspofungin (INN; brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc.. It is a member of a class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall.
Classification	Small molecule
Drug class	antifungal antibiotics (undefined group)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O